(Q28217400)

English

The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor

scientific article (publication date: 15 May 2006)

In more languages

Statements

scholarly article

0 references

The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor (English)

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

J L Goldstein

1

0 references

S C Lowry

2

0 references

F L Lanza

3

0 references

H I Schwartz

4

0 references

W E Dodge

5

0 references

language of work or name

0 references

publication date

15 May 2006

0 references

Alimentary Pharmacology & Therapeutics

0 references

23

0 references

10

0 references

1489-98

0 references

Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.02912.X

21 April 2017

Low-dose aspirin for the prevention of atherothrombosis

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.02912.X

21 April 2017

Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.02912.X

21 April 2017

Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.02912.X

21 April 2017

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.02912.X

21 April 2017

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.02912.X

21 April 2017

Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.02912.X

21 April 2017

Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.02912.X

21 April 2017

Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.02912.X

21 April 2017

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.02912.X

21 April 2017

Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.02912.X

21 April 2017

Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.02912.X

21 April 2017

COX-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: is either approach sufficient for patients at highest risk of NSAID-induced ulcers?

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.02912.X

21 April 2017

NSAID-associated deaths: the rise and fall of NSAID-associated GI mortality

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.02912.X

21 April 2017

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.02912.X

21 April 2017

Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.02912.X

21 April 2017

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2006.02912.X

21 April 2017

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02912.X

21 April 2017

Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02912.X

21 January 2018

Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02912.X

21 January 2018

Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02912.X

21 January 2018

Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02912.X

21 January 2018

The coxibs, selective inhibitors of cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02912.X

21 January 2018

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02912.X

21 January 2018

Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02912.X

21 January 2018

Prophylactic aspirin and risk of peptic ulcer bleeding

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02912.X

21 January 2018

Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02912.X

21 January 2018

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02912.X

21 January 2018

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02912.X

21 January 2018

Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02912.X

21 January 2018

Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02912.X

21 January 2018

Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02912.X

21 January 2018

Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02912.X

21 January 2018

Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02912.X

21 January 2018

Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02912.X

21 January 2018

Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02912.X

21 January 2018

Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02912.X

21 January 2018

Identifiers

10.1111/J.1365-2036.2006.02912.X

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28217400&oldid=1365078061"